Clinical data | |
---|---|
Pronunciation | /taɪˈæɡəbiːn/ |
Trade names | Gabitril |
AHFS/Drugs.com | Monograph |
MedlinePlus | a698014 |
Pregnancy category |
|
Routes of administration | Oral (tablets) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 90–95%[2] |
Protein binding | 96%[2] |
Metabolism | Hepatic (CYP450 system,[2] primarily CYP3A)[3] |
Onset of action | Tmax = 45 min[3] |
Elimination half-life | 5–8 hours[4] |
Excretion | Fecal (63%) and renal (25%)[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H25NO2S2 |
Molar mass | 375.55 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Tiagabine (trade name Gabitril) is an anticonvulsant medication produced by Cephalon that is used in the treatment of epilepsy. The drug is also used off-label in the treatment of anxiety disorders and panic disorder.